| License: Creative Commons Attribution 4.0 PDF - Published Version (3MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-442102
- DOI to cite this document:
- 10.5283/epub.44210
Abstract
The programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis blockade has been implemented in advanced-stage tumor therapy for various entities, including head and neck squamous cell carcinoma (HNSCC). Despite a promising tumor response in a subgroup of HNSCC patients, the majority suffer from disease progression. PD-L1 is known to influence several intrinsic mechanisms ...

Owner only: item control page


Download Statistics